Importance of serum interleukin-6 as a mediator of systemic inflammation in patients with alpha-1 antitrypsin deficiency;Importancia de la medición de la interleucina 6 en suero como mediador de inflamación sistémica en pacientes con deficiencia de alfa-1-antitripsina

Archivos de Bronconeumologia

Volumn 38, Issue 6, 2002, Pages 263-266

  Vila S ^a   Miravitlles, M ^a   Campos, F ^a   De La Roza, C ^a   Segura, R ^a   Morell, F ^a   Vidal, R ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Alpha 1 antitrypsin deficiency; Chronic obstructive pulmonary disease (COPD); Interleukin 6 (IL 6); Soluble receptor of IL 6 (SRIL 6)

Indexed keywords

ALPHA 1 ANTITRYPSIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; BLOOD; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; STATISTICAL ANALYSIS;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; DATA INTERPRETATION, STATISTICAL; FORCED EXPIRATORY VOLUME; HUMANS; INFLAMMATION; INTERLEUKIN-6; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, INTERLEUKIN-6;

EID: 0347309518     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-2896(02)75210-1     Document Type: Article

References (15)

1. Stockley RA. Alpha-1-antitrypsin deficiency: what next? Thorax 2000;55:614-8.
2. Breit SN, Robinson JP, Luckhurst E, Clark P, Penny R. Immunoregulation by alpha 1 antitrypsin. J Clin Lab Immunol 1982;7:127.
3. Breit SN, Wakelfield D, Robinson JP, Luckhurst E, Clark P, Penny R. The role of alpha-1-antitrypsin deficiency in the patho genesis of immune disorders. Clin Immunol 1985;35:363-80.
4. Hafeez W, Ciliberto G, Perlmutter DH. Constitutive and modulated expression of the human alpha-1-antitrypsin gene-different transcriptional initiation sites used in three different cell types. J Clin Investig 1992;89:1214-22.
5. Cichy J, Potempa J, Travis J. Biosynthesis of alpha-1-proteinase inhibitor by human lung-derived epithelial cells. J Biol Chem 1997;272:8250-2.
6. Jones SA, Horiuchi S, Topley N, Ymaamoto N, Fuller GM. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 2001;15:43-58.
7. Grupo de Trabajo de la SEPAR para la Práctica de la Espirometrí: en Clínica. Normativa para la práctica de la espirometría forzada Arch Bronconeumol 1989;25:132-42.
8. Roca J, Sanchis J, Agusti-Vidal A, Segarra F, Navajas D, Rodríguez-Roisín R, et al. Spirometric reference values from a Mediterranean population. Bull Eur Physiopathol Respir 1986;22:217-24.
9. Vidai E, Miravitlles M, Jardí R, Torrella M, Rodríguez-Frías F, Moral P, et al. Estudio de la frecuencia de los diferentes fenotipos de la alfa-1-antitripsina en una población de Barcelona. Med Clin (Barc) 1996;107:211-4.
10. Helle M, Boeije L, De Groot E, De Vos A, Aarden L. Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: synovial fluids and sera. J Immunol Methods 1991;138:47-56.
11. 1-antitrypsin enhancer results in an interleukin-6-deficient acute-phase response due to loss of cooperativity between transcription factors. Biochim Biophys Acta 1997;1362:67-76.
12. Bhowmik A, Seemungal TAR, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114-20.
13. 1-proteinase inhibitor synthesis in human lung derived epithelial cells. Biochem J 1998;329:335-9.
14. Miravitlles M, De Gracia J, Rodrigo M, Cruz MJ, Vendrell M, Vidal R, et al. Specific antibody response against the 23-valent pneumococcal vaccine in patients with alpha(1)-antitrypsin deficiency with and without bronchiectasis. Chest 1999;116:946-52.
15. Miravitlles M, Vidal R, Barros-Tizón JC, Bustamante A, España PP, Casas F, et al. Usefulness of a national Registry of alpha-1-antitrypsin deficiency. The Spanish experience. Respir Med 1998; 92:1181-7.